Source 1primary paper2025MED
Toolkit/dual-antigen CARs
dual-antigen CARs
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
This "evasion-to-solution" framework highlights how innovations such as dual-antigen CARs... directly mitigate known mechanisms that lead to therapeutic failure.
Usefulness & Problems
Why this is useful
Dual-antigen CARs are presented as a next-generation CAR engineering solution within the review's evasion-to-solution framework.; mitigating tumor immune-evasion mechanisms; next-generation CAR-NK engineering
Source:
Dual-antigen CARs are presented as a next-generation CAR engineering solution within the review's evasion-to-solution framework.
Source:
mitigating tumor immune-evasion mechanisms
Source:
next-generation CAR-NK engineering
Problem solved
The abstract states that they directly mitigate known mechanisms leading to therapeutic failure.; addressing mechanisms that lead to therapeutic failure
Source:
The abstract states that they directly mitigate known mechanisms leading to therapeutic failure.
Source:
addressing mechanisms that lead to therapeutic failure
Problem links
addressing mechanisms that lead to therapeutic failure
LiteratureThe abstract states that they directly mitigate known mechanisms leading to therapeutic failure.
Source:
The abstract states that they directly mitigate known mechanisms leading to therapeutic failure.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Mechanisms
multi-antigen targetingTechniques
Computational DesignTarget processes
editingsignalingImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: regulator
Operational role: regulator. Implementation mode: genetically encoded. Cofactor status: cofactor requirement unknown.
Independent follow-up evidence is still limited. Validation breadth across biological contexts is still narrow. Independent reuse still looks limited, so the evidence base may be fragile. No canonical validation observations are stored yet, so context-specific performance remains under-specified.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
CAR-NK cells are presented as a promising alternative to CAR-T therapies with reduced toxicity, allogeneic feasibility, and flexible manufacturing.
Chimeric antigen receptor-modified natural killer (CAR-NK) cells are emerging as a promising alternative to CAR-T therapies, offering advantages such as reduced toxicity, allogeneic feasibility, and flexible manufacturing.
Dual-antigen CARs, low-affinity designs, NK-specific signaling, iPSC-derived NK platforms, and multiplex gene editing are highlighted as innovations that directly mitigate known mechanisms leading to therapeutic failure.
This "evasion-to-solution" framework highlights how innovations such as dual-antigen CARs, low-affinity designs, NK-specific signaling, iPSC-derived NK platforms, and multiplex gene editing directly mitigate known mechanisms that lead to therapeutic failure.
Linking tumor biology to engineering strategy provides a translational roadmap for rational design of more adaptable and resilient CAR-NK therapies.
By linking tumor biology to engineering strategy, this review offers a translational roadmap for the rational design of more adaptable and resilient CAR-NK therapies.
Approval Evidence
1 source1 linked approval claimfirst-pass slug dual-antigen-cars
This "evasion-to-solution" framework highlights how innovations such as dual-antigen CARs... directly mitigate known mechanisms that lead to therapeutic failure.
Source:
mechanism mitigationsupports
Dual-antigen CARs, low-affinity designs, NK-specific signaling, iPSC-derived NK platforms, and multiplex gene editing are highlighted as innovations that directly mitigate known mechanisms leading to therapeutic failure.
This "evasion-to-solution" framework highlights how innovations such as dual-antigen CARs, low-affinity designs, NK-specific signaling, iPSC-derived NK platforms, and multiplex gene editing directly mitigate known mechanisms that lead to therapeutic failure.
Source:
Comparisons
Source-backed strengths
presented as a direct mitigation strategy for known immune-evasion mechanisms
Source:
presented as a direct mitigation strategy for known immune-evasion mechanisms
Compared with CAR-NK cells
dual-antigen CARs and CAR-NK cells address a similar problem space because they share editing, signaling.
Shared frame: same top-level item type; shared target processes: editing, signaling
Relative tradeoffs: appears more independently replicated; looks easier to implement in practice.
Compared with Chimeric Antigen Receptor (CAR) T-cell therapy
dual-antigen CARs and Chimeric Antigen Receptor (CAR) T-cell therapy address a similar problem space because they share editing, signaling.
Shared frame: same top-level item type; shared target processes: editing, signaling
Relative tradeoffs: appears more independently replicated; looks easier to implement in practice.
Compared with low-affinity designs
dual-antigen CARs and low-affinity designs address a similar problem space because they share editing, signaling.
Shared frame: same top-level item type; shared target processes: editing, signaling
Ranked Citations
- 1.